查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1472260

HIV注射市场：依通路划分：2024-2033年全球机会分析与产业预测

HIV Injection Market By Distribution Channel (Hospital Pharmacy, Drugs Stores and Retail Pharmacies, Others): Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 197 Pages | 商品交期: 2-3个工作天内

价格

HIV注射剂市场预计到2023年将达到10亿美元，2024年至2033年复合年增长率为17.9%，到2033年将达到55亿美元。

人类免疫力缺乏病毒 (HIV) 是一种攻击免疫系统的病毒，特别是 CD4 细胞（T 细胞），可帮助免疫系统抵抗感染疾病。爱滋病毒主要透过无保护的性行为、共用污染的针头以及分娩和哺乳期间受感染的母亲传播给婴儿。抗逆转录病毒疗法 (ART) 的进步显着改善了爱滋病毒感染者的预后，有助于控制病毒、防止进展为爱滋病并提高整体生活品质。定期检测、早期发现和获得医疗保健对于控制爱滋病毒和防止其传播至关重要。

HIV注射剂市场-IMG1

公众意识、教育和持续研究对于全世界对抗这种感染疾病的努力至关重要。 HIV 注射旨在将抗逆转录病毒物直接输送到血液中，保持体内药物水平有效且恆定。这些注射剂有不同的形式，包括肌肉注射（注射到肌肉）和皮下注射（注射到皮下）。 HIV注射剂市场的驱动因素包括：HIV感染者数量的增加、注射製剂中新型抗逆转录病毒药物的开发和引入、对长效和长效HIV预防和治疗方法的需求增加以及研究和开发活动的增加是由投资增加、政府针对爱滋病毒的倡议和扩大的医疗保健政策所推动的。

例如，根据联合国爱滋病毒/爱滋病联合规划署 (UNAIDS) 的数据，到 2022 年，全球将有 3,900 万人感染爱滋病毒。因此，爱滋病毒感染人数的增加将增加爱滋病毒注射剂的需求并推动市场成长。此外，爱滋病毒治疗领域的持续研究和开发工作预计将带来持续进步，并成为市场成长的驱动力。新型抗逆转录病毒药物（尤其是注射剂）的推出为医疗保健专业人员和患者提供了更多的病毒管理选择，从而推动了市场成长。例如，葛兰素史克公司生产了一种治疗爱滋病毒的长效注射抗逆转录病毒药物，该药物结合了卡博特韦和利匹韦林。此方案称为 Cabenuva（Vocabria，欧洲为 Recambis），由肌肉注射 cabotegravir（一种整合酶抑制剂）和利匹韦林（一种非核苷逆转录酶抑制剂）组成。这种长效注射疗法已在几个高所得国家获得核准，并显示出维持病毒抑制的前景。

此外，旨在扩大爱滋病毒治疗范围和改善医疗基础设施的政府措施和医疗政策正在发挥关键作用，预计将推动市场成长。例如，由美国卫生与公共服务部 (HHS)主导的终结爱滋病毒流行 (EHE)倡议旨在到 2025 年和 2030 年将美国新发爱滋病毒感染人数减少 75%。 HHS 致力于利用爱滋病毒预防、诊断、治疗和疫情应对方面的科学进步来解决种族、民族和地理差异。

然而，低度开发国家严格的审批监管程序和缺乏爱滋病预防教育是阻碍爱滋病注射市场成长的因素。相较之下，爱滋病毒药物的不断增加和新兴国家的高成长潜力为市场成长提供了有利的机会。例如，临床阶段免疫治疗公司 ImmunityBio, Inc. 于 2021 年 6 月宣布了其 HIV 临床管道，目前正在美国招募参与者，其中包括 Anktiva (N-803) 的 HIV 治癒试验。该试验预计将检验在参与者停止抗逆转录病毒治疗（ART）并受到密切监测后，Anktiva 是否可以单独或合併中和抗体（bNAB）控制 HIV。

HIV注射剂市场按分销管道和地区划分。依分销管道划分，市场分为医院药房、药局和零售药房等。依地区划分，我们有北美（美国、加拿大、墨西哥）、欧洲（德国、法国、英国、义大利、西班牙、其他欧洲国家地区）、亚太地区（日本、中国、印度、澳洲、韩国、其他亚洲地区）太平洋地区）、拉丁美洲、中东和非洲（巴西、中国、非洲、阿拉伯、拉丁美洲其他地区、中东和非洲）。

相关人员的主要利益

  • 本报告定量分析了 2023 年至 2033 年 HIV 注射市场的细分市场、当前趋势、估计/趋势和动态，并确定了 HIV 注射市场的强大机会。
  • 我们提供市场研究以及与市场驱动因素、市场限制和市场机会相关的资讯。
  • 波特的五力分析强调买家和供应商帮助相关人员做出利润驱动的商业决策并加强供应商和买家网路的潜力。
  • 对爱滋病毒注射市场细分的详细分析有助于识别市场机会。
  • 每个地区的主要国家都根据其对全球市场的收益贡献绘製了地图。
  • 市场参与者定位有助于基准化分析，并提供对市场参与者当前地位的清晰了解。
  • 该报告包括对区域和全球爱滋病毒注射市场趋势、主要企业、细分市场、应用领域和市场成长策略的分析。

报告客製化的可能性（请联络销售人员以了解额外费用和时间表）

  • 国家、区域和全球各级的患者/流行病学资料
  • 监管指引
  • 根据客户兴趣新增其他公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 十字交叉细分市场分析 - 市场规模与预测
  • 公司简介的扩充列表
  • 历史市场资料
  • SWOT分析

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 主要影响因素
    • 关键投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 更多人接受爱滋病毒治疗
      • 政府对爱滋病毒的认知与倡议不断增强
      • 产品核可数量增加
    • 抑制因素
      • 严格的核准流程
    • 机会
      • 新兴市场的高成长潜力
      • 研发线产品增加

第四章 HIV 注射市场：按分销管道

  • 概述
  • 医院药房
  • 药局/零售药房
  • 其他的

第五章 HIV 注射市场：按地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 其他亚太地区
  • 拉丁美洲、中东/非洲
    • 巴西
    • 沙乌地阿拉伯
    • 南非
    • 其他拉丁美洲、中东/非洲

第六章 竞争状况

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2023年主要企业定位

第七章 公司简介

  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • ImmunityBio, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Theratechnologies Inc.
  • Viriom, Inc.
  • AbbVie Inc.
  • Brii Biosciences
  • Shionogi & Co., Ltd.
Product Code: A312373

The HIV injection market was valued at $1 billion in 2023 and is estimated to reach $5.5 billion by 2033, exhibiting a CAGR of 17.9% from 2024 to 2033. Human immunodeficiency virus (HIV) is a virus that attacks the immune system, specifically the CD4 cells (T cells), which help the immune system fight off infections. HIV is primarily transmitted through unprotected sexual intercourse, sharing of contaminated needles, and from an infected mother to her baby during childbirth or breastfeeding. Advances in antiretroviral therapy (ART) have significantly improved the prognosis for people living with HIV, helping to control the virus, prevent the progression to AIDS, and enhance overall quality of life. Regular testing, early detection, and access to medical care are crucial in managing and preventing the spread of HIV.

HIV Injection Market - IMG1

Public awareness, education, and ongoing research remain essential in the global effort to combat this infectious disease. HIV injections are designed to deliver antiretroviral drugs directly into the bloodstream, ensuring effective and consistent levels of the medication in the body. These injections can come in various forms, including intramuscular injections (administered into the muscle) or subcutaneous injections (administered just beneath the skin). The HIV injection market is driven by rise in the number of people suffering from HIV, development and introduction of novel antiretroviral drugs in injectable formulations, rise in demand for long acting and extended delivery HIV prevention and treatment regimens, rise in investment in R and D activities, and growing government initiatives and healthcare policies for HIV.

For instance, according to the Joint United Nations Program on HIV and AIDS (UNAIDS), 39 million people globally were living with HIV in 2022. Thus, rise in the number of HIV cases increases the demand for HIV injections and drives the growth of market. In addition, ongoing R and D efforts in the field of HIV treatment led to continuous advancements which is expected to drive the market growth. The introduction of novel antiretroviral drugs, particularly those in injectable formulations, provides healthcare providers and patients with more options for managing the virus, thereby driving market growth. For instance, GlaxoSmithKline plc company manufactured combination of cabotegravir and rilpivirine, a long-acting injectable antiretroviral drug for the treatment of HIV. This regimen, known as Cabenuva (Vocabria and Rekambys in Europe), involves the intramuscular injection of cabotegravir, an integrase inhibitor, and rilpivirine, a non-nucleoside reverse transcriptase inhibitor. This long-acting injectable regimen has been approved in several high-income countries and has shown promise in maintaining viral suppression.

Furthermore, the government initiatives and healthcare policies, aimed at expanding access to HIV treatment and improving healthcare infrastructure, play a pivotal role, which is expected to drive the market growth. For instance, Ending the HIV Epidemic (EHE) initiative, coordinated by the U.S. Department of Health and Human Services (HHS) aims to reduce the number of new HIV infections in the U.S. by 75% by 2025 and then by at least 90% by 2030. It focuses on leveraging scientific advances in HIV prevention, diagnosis, treatment, and outbreak response to address racial, ethnic, and geographic disparities.

However, the stringent regulatory process for approval and lack of education about HIV prevention in underdeveloped countries are factors responsible for impeding the growth of the HIV injection market. In contrast, rise in number of pipeline drugs for HIV and high growth potential in emerging countries provides lucrative opportunity to the market growth. For instance, in June 2021, ImmunityBio, Inc., a clinical-stage immunotherapy company, announced its HIV clinical pipeline with an HIV cure study using Anktiva (N-803), which is now enrolling participants in the U.S. The trial is expected to study whether Anktiva can control HIV alone or together with combination broadly neutralizing antibodies (bNABs) after participants stop their antiretroviral therapy (ART) and they are carefully monitored.

The HIV injection market is segmented on the basis of distribution channel and region. By distribution channel, the market is classified into hospital pharmacy, drug stores and retail pharmacy, and others. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global HIV injection market are GlaxoSmithKline plc, Johnson and Johnson, Gilead Sciences, Inc., ImmunityBio, Inc., F. Hoffmann-La Roche Ltd, Theratechnologies Inc., Viriom, Inc., Shionogi & Co., Ltd., AbbVie Inc., and Brii Biosciences. Key players operating in the market have adopted product approvals, partnership, expansion, agreement, and clinical trial as their key strategies to expand their product portfolio.

Key Benefits for Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hiv injection market analysis from 2023 to 2033 to identify the prevailing hiv injection market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the hiv injection market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global hiv injection market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Criss-cross segment analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Distribution Channel

  • Others
  • Hospital Pharmacy
  • Drugs Stores and Retail Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Gilead Sciences, Inc.
    • F. Hoffmann-La Roche Ltd.
    • AbbVie Inc.
    • Shionogi & Co., Ltd.
    • ImmunityBio, Inc.
    • Theratechnologies Inc.
    • Viriom, Inc.
    • Brii Biosciences

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate bargaining power of suppliers
    • 3.3.2. Moderate threat of new entrants
    • 3.3.3. Moderate threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in number of people receiving HIV therapy
      • 3.4.1.2. Growing awareness & initiatives taken by government for HIV
      • 3.4.1.3. Rise in number of product approvals
    • 3.4.2. Restraints
      • 3.4.2.1. Stringent regulatory processes for the approval
    • 3.4.3. Opportunities
      • 3.4.3.1. High growth potential in emerging markets
      • 3.4.3.2. Rise in number of pipeline products

CHAPTER 4: HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Hospital Pharmacy
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Drugs Stores and Retail Pharmacies
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: HIV INJECTION MARKET, BY REGION

  • 5.1. Overview
    • 5.1.1. Market size and forecast By Region
  • 5.2. North America
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by Distribution Channel
    • 5.2.3. Market size and forecast, by country
      • 5.2.3.1. U.S.
      • 5.2.3.1.1. Market size and forecast, by Distribution Channel
      • 5.2.3.2. Canada
      • 5.2.3.2.1. Market size and forecast, by Distribution Channel
      • 5.2.3.3. Mexico
      • 5.2.3.3.1. Market size and forecast, by Distribution Channel
  • 5.3. Europe
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by Distribution Channel
    • 5.3.3. Market size and forecast, by country
      • 5.3.3.1. Germany
      • 5.3.3.1.1. Market size and forecast, by Distribution Channel
      • 5.3.3.2. France
      • 5.3.3.2.1. Market size and forecast, by Distribution Channel
      • 5.3.3.3. UK
      • 5.3.3.3.1. Market size and forecast, by Distribution Channel
      • 5.3.3.4. Italy
      • 5.3.3.4.1. Market size and forecast, by Distribution Channel
      • 5.3.3.5. Spain
      • 5.3.3.5.1. Market size and forecast, by Distribution Channel
      • 5.3.3.6. Rest of Europe
      • 5.3.3.6.1. Market size and forecast, by Distribution Channel
  • 5.4. Asia-Pacific
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by Distribution Channel
    • 5.4.3. Market size and forecast, by country
      • 5.4.3.1. Japan
      • 5.4.3.1.1. Market size and forecast, by Distribution Channel
      • 5.4.3.2. China
      • 5.4.3.2.1. Market size and forecast, by Distribution Channel
      • 5.4.3.3. India
      • 5.4.3.3.1. Market size and forecast, by Distribution Channel
      • 5.4.3.4. Australia
      • 5.4.3.4.1. Market size and forecast, by Distribution Channel
      • 5.4.3.5. South Korea
      • 5.4.3.5.1. Market size and forecast, by Distribution Channel
      • 5.4.3.6. Rest of Asia-Pacific
      • 5.4.3.6.1. Market size and forecast, by Distribution Channel
  • 5.5. LAMEA
    • 5.5.1. Key market trends, growth factors and opportunities
    • 5.5.2. Market size and forecast, by Distribution Channel
    • 5.5.3. Market size and forecast, by country
      • 5.5.3.1. Brazil
      • 5.5.3.1.1. Market size and forecast, by Distribution Channel
      • 5.5.3.2. Saudi Arabia
      • 5.5.3.2.1. Market size and forecast, by Distribution Channel
      • 5.5.3.3. South Africa
      • 5.5.3.3.1. Market size and forecast, by Distribution Channel
      • 5.5.3.4. Rest of LAMEA
      • 5.5.3.4.1. Market size and forecast, by Distribution Channel

CHAPTER 6: COMPETITIVE LANDSCAPE

  • 6.1. Introduction
  • 6.2. Top winning strategies
  • 6.3. Product mapping of top 10 player
  • 6.4. Competitive dashboard
  • 6.5. Competitive heatmap
  • 6.6. Top player positioning, 2023

CHAPTER 7: COMPANY PROFILES

  • 7.1. GlaxoSmithKline plc
    • 7.1.1. Company overview
    • 7.1.2. Key executives
    • 7.1.3. Company snapshot
    • 7.1.4. Operating business segments
    • 7.1.5. Product portfolio
    • 7.1.6. Business performance
    • 7.1.7. Key strategic moves and developments
  • 7.2. Johnson & Johnson
    • 7.2.1. Company overview
    • 7.2.2. Key executives
    • 7.2.3. Company snapshot
    • 7.2.4. Operating business segments
    • 7.2.5. Product portfolio
    • 7.2.6. Business performance
    • 7.2.7. Key strategic moves and developments
  • 7.3. Gilead Sciences, Inc.
    • 7.3.1. Company overview
    • 7.3.2. Key executives
    • 7.3.3. Company snapshot
    • 7.3.4. Operating business segments
    • 7.3.5. Product portfolio
    • 7.3.6. Business performance
    • 7.3.7. Key strategic moves and developments
  • 7.4. ImmunityBio, Inc.
    • 7.4.1. Company overview
    • 7.4.2. Key executives
    • 7.4.3. Company snapshot
    • 7.4.4. Operating business segments
    • 7.4.5. Product portfolio
    • 7.4.6. Business performance
    • 7.4.7. Key strategic moves and developments
  • 7.5. F. Hoffmann-La Roche Ltd.
    • 7.5.1. Company overview
    • 7.5.2. Key executives
    • 7.5.3. Company snapshot
    • 7.5.4. Operating business segments
    • 7.5.5. Product portfolio
    • 7.5.6. Business performance
  • 7.6. Theratechnologies Inc.
    • 7.6.1. Company overview
    • 7.6.2. Key executives
    • 7.6.3. Company snapshot
    • 7.6.4. Operating business segments
    • 7.6.5. Product portfolio
    • 7.6.6. Business performance
    • 7.6.7. Key strategic moves and developments
  • 7.7. Viriom, Inc.
    • 7.7.1. Company overview
    • 7.7.2. Key executives
    • 7.7.3. Company snapshot
    • 7.7.4. Operating business segments
    • 7.7.5. Product portfolio
  • 7.8. AbbVie Inc.
    • 7.8.1. Company overview
    • 7.8.2. Key executives
    • 7.8.3. Company snapshot
    • 7.8.4. Operating business segments
    • 7.8.5. Product portfolio
    • 7.8.6. Business performance
  • 7.9. Brii Biosciences
    • 7.9.1. Company overview
    • 7.9.2. Key executives
    • 7.9.3. Company snapshot
    • 7.9.4. Operating business segments
    • 7.9.5. Product portfolio
    • 7.9.6. Business performance
  • 7.10. Shionogi & Co., Ltd.
    • 7.10.1. Company overview
    • 7.10.2. Key executives
    • 7.10.3. Company snapshot
    • 7.10.4. Operating business segments
    • 7.10.5. Product portfolio
    • 7.10.6. Business performance
    • 7.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 02. HIV INJECTION MARKET FOR HOSPITAL PHARMACY, BY REGION, 2023-2033 ($MILLION)
  • TABLE 03. HIV INJECTION MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY REGION, 2023-2033 ($MILLION)
  • TABLE 04. HIV INJECTION MARKET FOR OTHERS, BY REGION, 2023-2033 ($MILLION)
  • TABLE 05. HIV INJECTION MARKET, BY REGION, 2023-2033 ($MILLION)
  • TABLE 06. NORTH AMERICA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 07. NORTH AMERICA HIV INJECTION MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 08. U.S. HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 09. CANADA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 10. MEXICO HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 11. EUROPE HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 12. EUROPE HIV INJECTION MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 13. GERMANY HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 14. FRANCE HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 15. UK HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 16. ITALY HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 17. SPAIN HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 18. REST OF EUROPE HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 19. ASIA-PACIFIC HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 20. ASIA-PACIFIC HIV INJECTION MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 21. JAPAN HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 22. CHINA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 23. INDIA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 24. AUSTRALIA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 25. SOUTH KOREA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 26. REST OF ASIA-PACIFIC HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 27. LAMEA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 28. LAMEA HIV INJECTION MARKET, BY COUNTRY, 2023-2033 ($MILLION)
  • TABLE 29. BRAZIL HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 30. SAUDI ARABIA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 31. SOUTH AFRICA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 32. REST OF LAMEA HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023-2033 ($MILLION)
  • TABLE 33. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 34. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 35. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 36. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 37. GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 38. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 39. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 40. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 41. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 42. JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 43. GILEAD SCIENCES, INC.: KEY EXECUTIVES
  • TABLE 44. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 45. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
  • TABLE 46. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 47. GILEAD SCIENCES, INC.: KEY STRATERGIES
  • TABLE 48. IMMUNITYBIO, INC.: KEY EXECUTIVES
  • TABLE 49. IMMUNITYBIO, INC.: COMPANY SNAPSHOT
  • TABLE 50. IMMUNITYBIO, INC.: PRODUCT SEGMENTS
  • TABLE 51. IMMUNITYBIO, INC.: PRODUCT PORTFOLIO
  • TABLE 52. IMMUNITYBIO, INC.: KEY STRATERGIES
  • TABLE 53. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 54. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 55. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 56. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 57. THERATECHNOLOGIES INC.: KEY EXECUTIVES
  • TABLE 58. THERATECHNOLOGIES INC.: COMPANY SNAPSHOT
  • TABLE 59. THERATECHNOLOGIES INC.: PRODUCT SEGMENTS
  • TABLE 60. THERATECHNOLOGIES INC.: PRODUCT PORTFOLIO
  • TABLE 61. THERATECHNOLOGIES INC.: KEY STRATERGIES
  • TABLE 62. VIRIOM, INC.: KEY EXECUTIVES
  • TABLE 63. VIRIOM, INC.: COMPANY SNAPSHOT
  • TABLE 64. VIRIOM, INC.: PRODUCT SEGMENTS
  • TABLE 65. VIRIOM, INC.: PRODUCT PORTFOLIO
  • TABLE 66. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 67. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 68. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 69. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 70. BRII BIOSCIENCES: KEY EXECUTIVES
  • TABLE 71. BRII BIOSCIENCES: COMPANY SNAPSHOT
  • TABLE 72. BRII BIOSCIENCES: PRODUCT SEGMENTS
  • TABLE 73. BRII BIOSCIENCES: PRODUCT PORTFOLIO
  • TABLE 74. SHIONOGI & CO., LTD.: KEY EXECUTIVES
  • TABLE 75. SHIONOGI & CO., LTD.: COMPANY SNAPSHOT
  • TABLE 76. SHIONOGI & CO., LTD.: PRODUCT SEGMENTS
  • TABLE 77. SHIONOGI & CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 78. SHIONOGI & CO., LTD.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. HIV INJECTION MARKET, 2023-2033
  • FIGURE 02. SEGMENTATION OF HIV INJECTION MARKET,2023-2033
  • FIGURE 03. TOP IMPACTING FACTORS IN HIV INJECTION MARKET (2022 TO 2032)
  • FIGURE 04. TOP INVESTMENT POCKETS IN HIV INJECTION MARKET (2024-2033)
  • FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 07. MODERATE THREAT OF SUBSTITUTES
  • FIGURE 08. MODERATE INTENSITY OF RIVALRY
  • FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 10. GLOBAL HIV INJECTION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. HIV INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023 AND 2033(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF HIV INJECTION MARKET FOR HOSPITAL PHARMACY, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF HIV INJECTION MARKET FOR DRUGS STORES AND RETAIL PHARMACIES, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF HIV INJECTION MARKET FOR OTHERS, BY COUNTRY 2023 AND 2033(%)
  • FIGURE 15. HIV INJECTION MARKET BY REGION, 2023 AND 2033(%)
  • FIGURE 16. U.S. HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 17. CANADA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 18. MEXICO HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 19. GERMANY HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 20. FRANCE HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 21. UK HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 22. ITALY HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 23. SPAIN HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 24. REST OF EUROPE HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 25. JAPAN HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 26. CHINA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 27. INDIA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 28. AUSTRALIA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 29. SOUTH KOREA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 30. REST OF ASIA-PACIFIC HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 31. BRAZIL HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 32. SAUDI ARABIA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 33. SOUTH AFRICA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 34. REST OF LAMEA HIV INJECTION MARKET, 2023-2033 ($MILLION)
  • FIGURE 35. TOP WINNING STRATEGIES, BY YEAR (2021-2023)
  • FIGURE 36. TOP WINNING STRATEGIES, BY DEVELOPMENT (2021-2023)
  • FIGURE 37. TOP WINNING STRATEGIES, BY COMPANY (2021-2023)
  • FIGURE 38. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 39. COMPETITIVE DASHBOARD
  • FIGURE 40. COMPETITIVE HEATMAP: HIV INJECTION MARKET
  • FIGURE 41. TOP PLAYER POSITIONING, 2023
  • FIGURE 42. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 43. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 44. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 45. JOHNSON & JOHNSON: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 46. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 47. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 48. GILEAD SCIENCES, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 49. IMMUNITYBIO, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 50. IMMUNITYBIO, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 51. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 53. THERATECHNOLOGIES INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 54. THERATECHNOLOGIES INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 55. ABBVIE INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 56. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 57. ABBVIE INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 58. BRII BIOSCIENCES: NET REVENUE, 2022-2022 ($MILLION)
  • FIGURE 59. SHIONOGI & CO., LTD.: NET REVENUE, 2021-2023 ($MILLION)